March 22, 2024Cancer Research

METTL3 Inhibition Suppresses Tumor Growth and Prolongs Survival in Solid Cancer Models

View Full Paper

Ask AI

Bookmark

Authors

GFGraeme FraserMcMaster University CSCatherine SorletBone Therapeutics NPNicolas ParmentierBone Therapeutics

Discussion

Member takes

Implication

Preclinical evaluation demonstrates tumor growth inhibition and extended survival in solid cancer mouse models, highlighting METTL3 inhibition as an effective therapeutic strategy.

Key Points

Pharmacological inhibition of METTL3 suppresses tumor growth and extends survival across solid tumor models, showing efficacy in nsclc, ovarian carcinoma, and squamous cell carcinoma.
Target engagement achieved an IC50 of 2 to 8 nM for m6a reduction across cell lines, while METTL3 enzymatic activity was potently suppressed with an overall IC50 of 2 nM in vitro.
Evaluation using scintillation proximity assay and mouse models tested daily M3i administration, tracking cellular viability alongside direct tumor growth inhibition across solid tumors.
Findings validate the rna methyltransferase METTL3 as a viable target for solid tumors, although these results rely on mouse models and require further translational validation.

Cite This Study

Fraser et al. (2024) studied this question.

synapsesocial.com/papers/68e72e1db6db6435876a725d https://doi.org/10.1158/1538-7445.am2024-3233

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation demonstrates tumor growth inhibition and extended survival in solid cancer mouse models, highlighting METTL3 inhibition as an effective therapeutic strategy.

METTL3 Inhibition Suppresses Tumor Growth and Prolongs Survival in Solid Cancer Models

Discussion

Member takes

Implication

Key Points

Cite This Study

METTL3 Inhibition Suppresses Tumor Growth and Prolongs Survival in Solid Cancer Models

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider